$TNYA
Tenaya Therapeutics Inc

2022 Q1 Form 10-K Financial Statement

#000095017022004426 Filed on March 23, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q4 2021
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $6.999M $5.211M $18.41M
YoY Change 99.12% 166.14% 135.67%
% of Gross Profit
Research & Development $24.16M $20.95M $54.39M
YoY Change 151.88% 150.63% 74.9%
% of Gross Profit
Depreciation & Amortization $966.0K $791.0K $2.961M
YoY Change 40.2% 20.21% 19.25%
% of Gross Profit
Operating Expenses $31.15M $26.16M $72.81M
YoY Change 137.73% 153.48% 87.1%
Operating Profit -$31.15M -$72.81M
YoY Change 137.73% 87.1%
Interest Expense $99.00K $67.00K $108.0K
YoY Change 1000.0% 1240.0% 24.14%
% of Operating Profit
Other Income/Expense, Net $98.00K -$54.00K $85.00K
YoY Change 1300.0% 5300.0% -83.56%
Pretax Income -$31.06M -$26.15M -$72.72M
YoY Change 137.1% 153.45% 89.4%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$31.06M -$26.15M -$72.70M
YoY Change 137.1% 153.45% 89.32%
Net Earnings / Revenue
Basic Earnings Per Share -$0.75 -$4.10
Diluted Earnings Per Share -$752.5K -$630.0K -$4.101M
COMMON SHARES
Basic Shares Outstanding 41.29M 41.28M 17.73M
Diluted Shares Outstanding 41.27M 17.73M

Balance Sheet

Concept 2022 Q1 2021 Q4 2021
SHORT-TERM ASSETS
Cash & Short-Term Investments $210.5M $251.3M $251.3M
YoY Change 63.86% 95.51%
Cash & Equivalents $25.97M $38.13M $38.13M
Short-Term Investments $184.5M $213.2M $213.2M
Other Short-Term Assets $3.328M $4.058M $4.058M
YoY Change 153.85% 183.97%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $213.8M $255.4M $255.4M
YoY Change 64.76% 96.48% 96.48%
LONG-TERM ASSETS
Property, Plant & Equipment $49.38M $43.02M $54.71M
YoY Change 92.29% 150.33% 218.33%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $6.579M $3.579M $4.126M
YoY Change 52.12% 669.68% 307.71%
Total Long-Term Assets $67.72M $58.83M $58.83M
YoY Change 125.66% 223.3% 223.3%
TOTAL ASSETS
Total Short-Term Assets $213.8M $255.4M $255.4M
Total Long-Term Assets $67.72M $58.83M $58.83M
Total Assets $281.5M $314.2M $314.2M
YoY Change 76.2% 112.06% 112.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.888M $10.72M $10.72M
YoY Change 324.86% 954.18% 954.18%
Accrued Expenses $8.132M $9.059M $10.89M
YoY Change 121.16% 186.59% 179.04%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.10M $21.77M $21.77M
YoY Change 223.1% 331.94% 331.94%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $212.0K $182.0K $13.89M
YoY Change -97.0% 857.89% 277.32%
Total Long-Term Liabilities $212.0K $182.0K $13.89M
YoY Change -97.0% 857.89% 277.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.10M $21.77M $21.77M
Total Long-Term Liabilities $212.0K $182.0K $13.89M
Total Liabilities $32.40M $35.66M $35.66M
YoY Change 149.9% 308.89% 308.89%
SHAREHOLDERS EQUITY
Retained Earnings -$186.6M -$155.5M
YoY Change 87.81%
Common Stock $4.000K $4.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $249.1M $278.5M $278.5M
YoY Change
Total Liabilities & Shareholders Equity $281.5M $314.2M $314.2M
YoY Change 76.2% 112.06% 112.06%

Cashflow Statement

Concept 2022 Q1 2021 Q4 2021
OPERATING ACTIVITIES
Net Income -$31.06M -$26.15M -$72.70M
YoY Change 137.1% 153.45% 89.32%
Depreciation, Depletion And Amortization $966.0K $791.0K $2.961M
YoY Change 40.2% 20.21% 19.25%
Cash From Operating Activities -$28.76M -$16.35M -$60.81M
YoY Change 82.13% 57.17% 71.56%
INVESTING ACTIVITIES
Capital Expenditures $8.595M -$12.55M $25.12M
YoY Change 98.82% 53.53% 157.31%
Acquisitions
YoY Change
Other Investing Activities $25.03M -$50.03M -$213.4M
YoY Change -7853.11%
Cash From Investing Activities $16.43M -$62.58M -$238.6M
YoY Change -480.15% 665.32% 3303.2%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $13.00K
YoY Change 1200.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 15.00K -21.00K 209.0M
YoY Change -99.93% -100.02% 41.9%
NET CHANGE
Cash From Operating Activities -28.76M -16.35M -60.81M
Cash From Investing Activities 16.43M -62.58M -238.6M
Cash From Financing Activities 15.00K -21.00K 209.0M
Net Change In Cash -12.31M -78.95M -90.41M
YoY Change 12587.63% -217.23% -186.26%
FREE CASH FLOW
Cash From Operating Activities -$28.76M -$16.35M -$60.81M
Capital Expenditures $8.595M -$12.55M $25.12M
Free Cash Flow -$37.35M -$3.793M -$85.93M
YoY Change 85.71% 70.55% 90.08%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
8600000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
142000
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021 dei Entity Central Index Key
EntityCentralIndexKey
0001858848
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Amendment Flag
AmendmentFlag
false
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.1667
CY2021 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2021 dei Document Type
DocumentType
10-K
CY2021 dei Document Annual Report
DocumentAnnualReport
true
CY2021 dei Document Period End Date
DocumentPeriodEndDate
2021-12-31
CY2021 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021 dei Document Transition Report
DocumentTransitionReport
false
CY2021 dei Entity File Number
EntityFileNumber
001-40656
CY2021 dei Entity Registrant Name
EntityRegistrantName
TENAYA THERAPEUTICS, INC.
CY2021 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
11685000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
547000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
547000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3579000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
465000
CY2021Q4 us-gaap Assets
Assets
314189000
CY2021 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-3789973
CY2021 dei Entity Address Address Line1
EntityAddressAddressLine1
171 Oyster Point Boulevard
CY2021 dei Entity Address Address Line2
EntityAddressAddressLine2
5th Floor
CY2021 dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
CY2021 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2021 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
CY2021 dei City Area Code
CityAreaCode
650
CY2021 dei Local Phone Number
LocalPhoneNumber
825-6900
CY2021Q4 us-gaap Liabilities
Liabilities
35663000
CY2020Q4 us-gaap Liabilities
Liabilities
8722000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
213171000
CY2021 dei Security12b Title
Security12bTitle
Common Stock $0.0001 par value per share
CY2021 dei Trading Symbol
TradingSymbol
TNYA
CY2021 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4058000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1429000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
255358000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
129964000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43020000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17185000
CY2021 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2021 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2021 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2021 dei Entity Small Business
EntitySmallBusiness
true
CY2021 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2021 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2021 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2021 dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Public Float
EntityPublicFloat
527747589
CY2022Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
41294053
CY2021 dei Auditor Firm
AuditorFirmId
34
CY2021 dei Auditor Name
AuditorName
Deloitte and Touche LLP
CY2021 dei Auditor Location
AuditorLocation
San Francisco, California
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38129000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128535000
CY2020Q4 us-gaap Assets
Assets
148161000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
10721000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1017000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9059000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3161000
CY2020Q4 tnya Deferred Rent And Other Lease Liabilities Current
DeferredRentAndOtherLeaseLiabilitiesCurrent
863000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1994000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
21774000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5041000
CY2020Q4 tnya Deferred Rent And Other Lease Liabilities Noncurrent
DeferredRentAndOtherLeaseLiabilitiesNoncurrent
3662000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
13707000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
182000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
19000
CY2020Q4 us-gaap Stockholders Equity Note Subscriptions Receivable
StockholdersEquityNoteSubscriptionsReceivable
87000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-141000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155533000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-82812000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
278526000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-81315000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
314189000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
148161000
CY2021 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
54393000
CY2021Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
26102301
CY2021Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2021Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
24493528
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
24493528
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
220754000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
200000000
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
1000000000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
30330000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
41291374
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
41291374
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1210306
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1210306
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
434196000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1584000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31099000
CY2021 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
18413000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7813000
CY2021 us-gaap Operating Expenses
OperatingExpenses
72806000
CY2020 us-gaap Operating Expenses
OperatingExpenses
38912000
CY2021 us-gaap Operating Income Loss
OperatingIncomeLoss
-72806000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-38912000
CY2021 us-gaap Investment Income Interest
InvestmentIncomeInterest
108000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
87000
CY2020 tnya Change In Fair Value Of Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfConvertiblePreferredStockTrancheLiability
-75000
CY2021 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-23000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
355000
CY2021 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
85000
CY2020 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
517000
CY2021 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-72721000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-38395000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-72721000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-38395000
CY2021 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-141000
CY2021 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-72862000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-38395000
CY2021 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.10
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-39.50
CY2021 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17734166
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
972091
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-43739000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
34000
CY2020 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
45000
CY2020 tnya Notes Receivable From Stockholders
NotesReceivableFromStockholders
-1000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
741000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-38395000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-81315000
CY2021 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
240735000
CY2021 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
188541000
CY2021 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
358000
CY2021 tnya Vesting Of Early Exercised Stock Options
VestingOfEarlyExercisedStockOptions
32000
CY2021 tnya Notes Receivable From Stockholders
NotesReceivableFromStockholders
87000
CY2021 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2950000
CY2021 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-141000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-72721000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
278526000
CY2021 us-gaap Profit Loss
ProfitLoss
-72721000
CY2020 us-gaap Profit Loss
ProfitLoss
-38395000
CY2021 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2961000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2483000
CY2021 tnya Amortization Of Premium On Marketable Securities
AmortizationOfPremiumOnMarketableSecurities
131000
CY2021 us-gaap Share Based Compensation
ShareBasedCompensation
2950000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
741000
CY2021 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-61000
CY2020 us-gaap Gain Loss On Disposition Of Assets
GainLossOnDispositionOfAssets
-33000
CY2021 tnya Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
1064000
CY2020 tnya Change In Fair Value Of Convertible Preferred Stock Tranche Liability
ChangeInFairValueOfConvertiblePreferredStockTrancheLiability
-75000
CY2021 tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
2730000
CY2020 tnya Increase Decrease In Prepaid Expense And Other Current Assets
IncreaseDecreaseInPrepaidExpenseAndOtherCurrentAssets
312000
CY2021 us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
3114000
CY2021Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
251300000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
38676000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
129082000
CY2021 us-gaap Operating Lease Payments
OperatingLeasePayments
6110000
CY2021 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
8558000
CY2021 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
240735000
CY2021 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4100000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
364000
CY2021 tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
3295000
CY2020 tnya Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
925000
CY2020 tnya Increase Decrease In Deferred Rent And Other Lease Liabilities
IncreaseDecreaseInDeferredRentAndOtherLeaseLiabilities
775000
CY2021 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-1472000
CY2021 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
163000
CY2020 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
-34000
CY2021 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-60812000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35447000
CY2021 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
25121000
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
9763000
CY2021 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
213443000
CY2020 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
2753000
CY2021 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-238564000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7010000
CY2021 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
188541000
CY2021 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
374000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
34000
CY2021 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
13000
CY2020 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
1000
CY2021 tnya Proceeds From Repayments On Notes Receivable From Stockholders
ProceedsFromRepaymentsOnNotesReceivableFromStockholders
87000
CY2021 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
208970000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
147268000
CY2021 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-90406000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
104811000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129082000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24271000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
38676000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
129082000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
38129000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
128535000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
547000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
547000
CY2020 us-gaap Stock Issued1
StockIssued1
711000
CY2020 tnya Offering Costs Related To Series C Convertible Preferred Stock Included In Accounts Payable And Accrued Expenses And Other Current Liabilities
OfferingCostsRelatedToSeriesCConvertiblePreferredStockIncludedInAccountsPayableAndAccruedExpensesAndOtherCurrentLiabilities
234000
CY2021Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-6
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-155500000
CY2021 us-gaap Net Income Loss
NetIncomeLoss
-72700000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-38400000
CY2021 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentrations of Credit Risk</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to concentration of risk consist principally of cash, cash equivalents and marketable securities. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains bank deposits in federally insured financial institutions, and these deposits may exceed federally insured limits</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is exposed to credit risk in the event of default by the financial institutions holding its cash and cash equivalents and the issuers of its investments in marketable securities to the extent recorded in the balance sheets. </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has not experienced any losses on its deposits of cash and cash equivalents.</span>
CY2021 us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and the disclosure of contingent assets and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">liabilities </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying financial statements include, but are not limited to, the fair value of common stock, the valuation of equity-based awards, the useful lives of property and equipment, the fair value of the convertible preferred stock tranche liability, accrued expenses related to research and development activities and the valuation allowance for deferred tax assets. The Company bases its estimates on historical experience, the current economic environment, and on various other assumptions that are believed to be reasonable under the circumstances. Actual results may differ from those estimates or assumptions.</span>
CY2021 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2020Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
500000
CY2021 tnya Impairment Charges On Marketable Securities Related To Other Than Temporary
ImpairmentChargesOnMarketableSecuritiesRelatedToOtherThanTemporary
0
CY2021Q4 tnya Convertible Preferred Stock Tranche Liability
ConvertiblePreferredStockTrancheLiability
0
CY2020Q4 tnya Convertible Preferred Stock Tranche Liability
ConvertiblePreferredStockTrancheLiability
0
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
2400000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3678000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3792000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3910000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2445000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
1386000
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6905000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
52445000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
23888000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
9425000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
6703000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
43020000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
17185000
CY2021 us-gaap Depreciation And Amortization
DepreciationAndAmortization
3000000.0
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2500000
CY2021Q4 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
3667000
CY2020Q4 tnya Accrued Compensation And Related Expenses
AccruedCompensationAndRelatedExpenses
2090000
CY2021Q4 tnya Accrued Property And Equipment
AccruedPropertyAndEquipment
2863000
CY2020Q4 tnya Accrued Property And Equipment
AccruedPropertyAndEquipment
231000
CY2021Q4 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2023000
CY2020Q4 tnya Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
391000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
344000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
328000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
162000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
121000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9059000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3161000
CY2021 us-gaap Operating Lease Expense
OperatingLeaseExpense
5700000
CY2021 us-gaap Short Term Lease Cost
ShortTermLeaseCost
1700000
CY2021 us-gaap Variable Lease Cost
VariableLeaseCost
1600000
CY2021 us-gaap Common Stock Voting Rights
CommonStockVotingRights
The holders of common stock are entitled to one vote per share on all matters to be voted on by the stockholders of the Company and are entitled to dividends, if and when declared by the board of directors, subject to the prior rights of the preferred stockholders.
CY2021Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
22116000
CY2021Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
6133000
CY2021Q4 tnya Lessee Operating Tenant Improvement Receivable
LesseeOperatingTenantImprovementReceivable
282000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
15701000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
3752000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2206000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2283000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2363000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
999000
CY2020Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11603000
CY2021 tnya Sublease Agreements Expiration Date
SubleaseAgreementsExpirationDate
2020-12-31
CY2020Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
26102301
CY2020Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
24493528
CY2020Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
24493528
CY2020Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
220754000
CY2020Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
227900000
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6366312
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
26066506
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1700000
CY2020Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
37000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
9.50
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
4.98
CY2021 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
901000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
293000
CY2021 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
2000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
466000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1470000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
571000
CY2021 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2950000
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
741000
CY2021Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
16700000
CY2021 tnya Share Based Compensation Arrangement By Share Based Payment Award Weighted Average Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardWeightedAveragePeriod
P3Y1M6D
CY2021Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
34746000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
20917000
CY2021Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4443000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
1346000
CY2021Q4 tnya Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
3362000
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.95
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.03
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.78
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.83
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.006
CY2021 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.014
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.004
CY2020 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.015
CY2021 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2021 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2021 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.081
CY2021 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.031
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.036
CY2021 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.003
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.003
CY2020 tnya Effective Income Tax Rate Reconciliation Limitation On Tax Attribute Carryforwards Percent
EffectiveIncomeTaxRateReconciliationLimitationOnTaxAttributeCarryforwardsPercent
0.090
CY2021 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.233
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.231
CY2021 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.011
CY2020 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
-0.003
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
571000
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
744000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
727000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities
1825000
CY2021Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
309000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
79000
CY2021Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
152000
CY2020Q4 us-gaap Deferred Tax Assets Property Plant And Equipment
DeferredTaxAssetsPropertyPlantAndEquipment
120000
CY2021Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
43739000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
24287000
CY2021Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
41281000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
24287000
CY2021Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2458000
CY2021Q4 tnya Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
2458000
CY2021 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
17000000.0
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
8900000
CY2021Q4 tnya Net Operating Losses State Expiration Begin Year
NetOperatingLossesStateExpirationBeginYear
2036
CY2021Q4 tnya Tax Credits Federal Expiration Begin Year
TaxCreditsFederalExpirationBeginYear
2036
CY2021 tnya Tax Credits State Expiration Description
TaxCreditsStateExpirationDescription
Do Not Expire
CY2020Q4 tnya Deferred Tax Assets Removed Related To Net Operating Loss Carryforwards And Research Tax Credit Carryforwards
DeferredTaxAssetsRemovedRelatedToNetOperatingLossCarryforwardsAndResearchTaxCreditCarryforwards
3100000
CY2021Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2801059
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
25792463

Files In Submission

Name View Source Status
0000950170-22-004426-index-headers.html Edgar Link pending
0000950170-22-004426-index.html Edgar Link pending
0000950170-22-004426.txt Edgar Link pending
0000950170-22-004426-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
img250189095_0.jpg Edgar Link pending
img250189095_1.jpg Edgar Link pending
img250189095_10.jpg Edgar Link pending
img250189095_11.jpg Edgar Link pending
img250189095_12.jpg Edgar Link pending
img250189095_13.jpg Edgar Link pending
img250189095_14.jpg Edgar Link pending
img250189095_15.jpg Edgar Link pending
img250189095_16.jpg Edgar Link pending
img250189095_17.jpg Edgar Link pending
img250189095_18.jpg Edgar Link pending
img250189095_19.jpg Edgar Link pending
img250189095_2.jpg Edgar Link pending
img250189095_20.jpg Edgar Link pending
img250189095_21.jpg Edgar Link pending
img250189095_22.jpg Edgar Link pending
img250189095_23.jpg Edgar Link pending
img250189095_24.jpg Edgar Link pending
img250189095_25.jpg Edgar Link pending
img250189095_26.jpg Edgar Link pending
img250189095_27.jpg Edgar Link pending
img250189095_28.jpg Edgar Link pending
img250189095_29.jpg Edgar Link pending
img250189095_3.jpg Edgar Link pending
img250189095_30.jpg Edgar Link pending
img250189095_31.jpg Edgar Link pending
img250189095_32.jpg Edgar Link pending
img250189095_33.jpg Edgar Link pending
img250189095_34.jpg Edgar Link pending
img250189095_35.jpg Edgar Link pending
img250189095_36.jpg Edgar Link pending
img250189095_37.jpg Edgar Link pending
img250189095_38.jpg Edgar Link pending
img250189095_39.jpg Edgar Link pending
img250189095_4.jpg Edgar Link pending
img250189095_40.jpg Edgar Link pending
img250189095_41.jpg Edgar Link pending
img250189095_42.jpg Edgar Link pending
img250189095_43.jpg Edgar Link pending
img250189095_44.jpg Edgar Link pending
img250189095_45.jpg Edgar Link pending
img250189095_46.jpg Edgar Link pending
img250189095_47.jpg Edgar Link pending
img250189095_48.jpg Edgar Link pending
img250189095_49.jpg Edgar Link pending
img250189095_5.jpg Edgar Link pending
img250189095_50.jpg Edgar Link pending
img250189095_51.jpg Edgar Link pending
img250189095_52.jpg Edgar Link pending
img250189095_53.jpg Edgar Link pending
img250189095_54.jpg Edgar Link pending
img250189095_55.jpg Edgar Link pending
img250189095_56.jpg Edgar Link pending
img250189095_57.jpg Edgar Link pending
img250189095_58.jpg Edgar Link pending
img250189095_59.jpg Edgar Link pending
img250189095_6.jpg Edgar Link pending
img250189095_60.jpg Edgar Link pending
img250189095_61.jpg Edgar Link pending
img250189095_62.jpg Edgar Link pending
img250189095_63.jpg Edgar Link pending
img250189095_64.jpg Edgar Link pending
img250189095_65.jpg Edgar Link pending
img250189095_66.jpg Edgar Link pending
img250189095_67.jpg Edgar Link pending
img250189095_68.jpg Edgar Link pending
img250189095_69.jpg Edgar Link pending
img250189095_7.jpg Edgar Link pending
img250189095_70.jpg Edgar Link pending
img250189095_71.jpg Edgar Link pending
img250189095_72.jpg Edgar Link pending
img250189095_73.jpg Edgar Link pending
img250189095_74.jpg Edgar Link pending
img250189095_75.jpg Edgar Link pending
img250189095_76.jpg Edgar Link pending
img250189095_77.jpg Edgar Link pending
img250189095_78.jpg Edgar Link pending
img250189095_79.jpg Edgar Link pending
img250189095_8.jpg Edgar Link pending
img250189095_9.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tnya-20211231.htm Edgar Link pending
tnya-20211231.xsd Edgar Link pending
tnya-20211231_cal.xml Edgar Link unprocessable
tnya-20211231_def.xml Edgar Link unprocessable
tnya-20211231_htm.xml Edgar Link completed
tnya-20211231_lab.xml Edgar Link unprocessable
tnya-20211231_pre.xml Edgar Link unprocessable
tnya-ex10_2.htm Edgar Link pending
tnya-ex23_1.htm Edgar Link pending
tnya-ex31_1.htm Edgar Link pending
tnya-ex31_2.htm Edgar Link pending
tnya-ex32_1.htm Edgar Link pending
tnya-ex4_3.htm Edgar Link pending